A Randomized, Double-Blind, Placebo-Controlled Trial: Efficacy of Opuntia ficus - indica Prebiotic Supplementation in Subjects with Gut Dysbiosis.

Gut dysbiosis refers to an imbalance in gut microbiota composition and function. Opuntia ficus-indica extract has been shown to modulate gut microbiota by improving SCFA production in vivo and gastrointestinal discomfort (GD) in humans. The aim of this study was to demonstrate the efficacy of Odilia...

Descripción completa

Detalles Bibliográficos
Publicado en:Nutrients Vol. 16; no. 5; pp. 586 - 609
Autores principales: Mellai, Marta, Allesina, Marta, Edoardo, Benedetto, Cascella, Federica, Nobile, Vincenzo, Spina, Amelia, Amone, Fabio, Zaccaria, Vincenzo, Insolia, Violetta, Perri, Anna, Lofaro, Danilo, Puoci, Francesco
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: MDPI Mar2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175991488&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 175991488
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20726643
        B0TT
      jtl: Nutrients
      issn: 20726643
      maglogo: N
    pubinfo:
      dt: Mar2024
      vid: 16
      iid: 5
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        175991488
        175991488
        175991488
        10.3390/nu16050586
        175991488
      ppf: 586
      ppct: 23
      formats:
      tig:
        atl: A Randomized, Double-Blind, Placebo-Controlled Trial: Efficacy of Opuntia ficus - indica Prebiotic Supplementation in Subjects with Gut Dysbiosis.
      aug:
        au:
          Mellai, Marta
          Allesina, Marta
          Edoardo, Benedetto
          Cascella, Federica
          Nobile, Vincenzo
          Spina, Amelia
          Amone, Fabio
          Zaccaria, Vincenzo
          Insolia, Violetta
          Perri, Anna
          Lofaro, Danilo
          Puoci, Francesco
        affil: Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy
      sug:
        subj:
          Gastrointestinal Diseases Drug Therapy
          Prebiotics Therapeutic Use
          Plant Extracts Therapeutic Use
          Dietary Supplements Therapeutic Use
          Drug Efficacy
          Plant Extracts Pharmacodynamics
          Inflammation
          Brain-Gut Axis Drug Effects
          Gut Microbiota Drug Effects
          Immunity Drug Effects
          Oxidative Stress Drug Effects
          Treatment Outcomes
          Human
          Male
          Female
          Sequence Analysis
          Randomized Controlled Trials
          Random Assignment
          Double-Blind Studies
          Descriptive Statistics
          Comparative Studies
          Placebo Effect
          Adult
          Genomics
          Funding Source
          Adult: 19-44 years
          Male
          Female
      ab: Gut dysbiosis refers to an imbalance in gut microbiota composition and function. Opuntia ficus-indica extract has been shown to modulate gut microbiota by improving SCFA production in vivo and gastrointestinal discomfort (GD) in humans. The aim of this study was to demonstrate the efficacy of OdiliaTM on gastrointestinal health by changing the microbial diversity of species involved in inflammation, immunity, oxidation, and the brain–gut–muscle axis. A randomized, double-blind clinical trial was conducted in 80 adults with gut dysbiosis. The intervention consisted of a 300 mg daily intake of OdiliaTM (n = 40) or maltodextrin as a placebo (n = 40), administered for 8 weeks. Intervention effect was evaluated using 16S metagenomics and GIQLI/GSAS scores at baseline, at 4 and 8 weeks. Eight weeks of OdiliaTM supplementation positively modulates gut microbiota composition with a significant reduction in the Firmicutes to Bacteroidetes ratio (p = 0.0012). Relative abundances of beneficial bacteria (Bacteroides and Clostridium_XIVa) were significantly increased (p < 0.001), in contrast to a significant reduction in pro-inflammatory bacteria (p < 0.001). Accordingly, GIQLI and GSAS scores revealed successful improvement in GD. OdiliaTM may represent an effective and well-tolerated treatment in subjects with gut dysbiosis.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N